Australian scientists develop nasal spray that can prevent SARS-Cavi-2 infection

Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to wreak havoc globally, so scientists are rushing to develop an effective drug or vaccine to fight the infection. Since the epidemic began in December 2019.5 More than 33. million people have been infected, finding treatment for infected people is crucial to preventing its spread.

Now, Australia-based biotech company Ana Resperi, which is developing a nasal spray that can help the human immune system fight the flu and common cold, has significantly reduced the development of coronavirus in a recent study of animals.

Potential nasal sprays will not only help treat COVID-19 but also prevent it.

Nasal spray

A novel product called INA-011, developed by Ana Resperi, and laboratory experiments show that it has reduced viral replication in animal studies by as much as one percent. The new study, led by Professor Miles Carroll, Deputy Director of Public Health England (PHE), describes a possible cure and is published in an open-source preprint server. bioRxiv*.

Used as a nasal spray, its purpose is to boost the body’s natural immune system to fight the common cold and flu. It works by stimulating the innate immune system, which is the body’s first line of defense against pathogenic infections. While the drug boosted the immune system, it also prevented SARS-CoV-2 infection and replication in the laboratory.

Clinical observations. (A) Schematic of experimental design. Ferrata received INNA-051 and PBS treatment 4 days and 1 day before to challenge with 5.0 x 106 pfu / ml SARS-CoV-2. Nasal wash and throat swabs were collected on day 1, 3, 5, 7, 10 and 12 post challenge (PC) for all treatment groups and control group. Scheduled culls were performed for 6/24 ferrets at 3 pcs per day and measured twice daily (except for about 8 hours) using 12-14 pcs (b) implanted temperature / ID chips. A standard error of average temperature +/- Mean (SEM) is displayed. Post-SARS-Covy-2 challenge of temperature sinking

Was grateful for the treason. (B) Percentage change from ferrate weight before daily weight was recorded and before treatment was planned. Average percentage weight change +/- SEM is displayed.

Clinical observations. (A) Schematic of experimental design. Ferret received INA-011 and PBS treatment 4 days and 1 day before to challenge with p.0 x 106 PFU / ml SARS-CV-2. Nasal wash and throat swabs were collected on days 1, 3, 5, 7, 10 and 12 for post-challenge (PC) for all treatment groups and control group. Scheduled buds were performed for 6/24 ferrets at 3 pcs per day and measured twice daily (except for about 8 hours) using 12-14 pcs (b) planted temperature / ID chips. A standard error of average temperature +/- Mean (SEM) is displayed. Post-SARS-Covy-2 challenge of temperature sinking

Was grateful for the treason. (B) Percentage change from ferrate weight before daily weight was recorded and before treatment was planned. Average percentage weight change +/- SEM is displayed.

Learning

Respiratory tract diseases, including the flu, common colds and coronavirus infections, pose major threats to global health. The virus causes epidemics, which endanger the lives of children, such as infants, the elderly, and immunocompromised people.

The SARS-Cavi-2 infection is actively spreading throughout the world, and it spreads rapidly from one person to another through close contact and respiratory drops. The biggest danger of the current epidemic is that many people infected with the virus are asymptomatic, which means they don’t know they carry the virus. As a result, they are called quiet spreaders.

A research team from the National Infection Service, Public Health England (PHE), wanted to develop a nasal spray to prevent virus replication in the nasal area, the most common cause of virus entry.

To test the nasal spray, the team obtained nasal wash and throat swab samples four days before the viral challenge. After analyzing viral RNA in nasal wash samples, the team confirmed infection in all treatment groups, with lower viral RNA levels seen in INNA-051 treatment.

The team found that prophylactic intra-nasal administration of INNA-051 in the SARS-Covi-2 ferrate infection model reduced the level and risk of viral RNA in the nose.

“The results of our study support the clinical development of prophylactic TLR2 / 6 congenital immunity based therapy in URT to reduce SARS-CoV-2 transmission and provide protection against COVD-19,” the team wrote in the paper.

Further, the research team added that prophylactic approaches are important for people at risk of community transmission or CO high risk of serious diseases from COVID-19, such as the elderly, people with comorbidities, and people with immunodeficiency.

“We were amazed at how effective our treatment was. By accelerating the natural immune response of ferrets through our treatment, we have seen rapid eradication of the virus, ”said Christoph DeMaisen, managing director of its respiratory system.

“If humans respond in the same way, the benefits of treatment are twofold. Individuals exposed to the virus will likely get rid of it rapidly, with treatment ensuring that the disease does not progress to mild symptoms. This is especially relevant for vulnerable members of the community. In addition, the severity of this response means that infected individuals are less likely to pass on it, meaning a faster pause in community transmission, ”he added. https://www.youtube.com/watch?v=AVkjoDG1ZVg